key: cord-1019108-jy4gzswf
authors: Asemota, Joseph; Aduli, Farshad
title: The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection
date: 2022-01-24
journal: Clin Liver Dis (Hoboken)
DOI: 10.1002/cld.1169
sha: f4f8f943c69791f9ca2677c4aa9216e7e49ff334
doc_id: 1019108
cord_uid: jy4gzswf

Content available: Audio Recording

Impact of NAFLD on COVID-19 Infection Asemota and Aduli review in high-income populations and an important cause of chronic liver disease. It is associated with a variety of factors, such as obesity, diabetes mellitus, and other components of the metabolic syndrome that are known to aggravate the severity of COVID-19. 3 Reports from some studies show that individuals with NAFLD have odds of testing positive for COVID-19 of 1.85, as well as an increased risk for having symptomatic COVID-19 infection. 4 They also describe a 6.4 higher odds of COVID-19 progression and longer viral shedding time in patients with NAFLD. 5 A significant proportion (ranging from 37% to 76%) of hospitalized patients with COVID-19 have been shown to have abnormalities in hepatic function tests, with derangements in hepatocellular enzymes often showing a myriad of hepatocellular, cholestatic, and mixed injury patterns. 6, 7 In particular, patients with derangements in transaminases have been shown to have higher mortality and overall worse outcomes. 8 Although the exact mechanism(s) for the gastrohepatic effects seen in SARS-CoV-2 infection remains unclear, it is postulated that the link between SARS-CoV-2 and hepatic injury may relate to viral biology and tropism. 9 SARS-CoV-2 is an enveloped positive-sense singlestranded RNA virus that shares about 80% of its genome sequence with SARS-CoV, the viral strain responsible for the 2003 SARS outbreak. 10 Similar to the SARS-CoV, it encodes and expresses the spike (S) glycoprotein, which is capable of using the angiotensin-converting enzyme-2 (ACE2) receptor, a membrane-bound aminopeptidase, as a functional receptor for cellular entry. 8 There is a high expression of ACE2 on the apical surface of polarized epithelial cells, and this correlates strongly with the differentiation state of the epithelia (i.e., increased expression in more differentiated epithelia). 11 Although the type II alveolar cells in the lungs have an abundance of ACE2 receptors, this receptor is also present within the gastrointestinal tract. In the hepatobiliary system, the ACE2 receptor is predominantly expressed in cholangiocytes (60% of cells) and endothelial cells, with minimal expression on hepatocytes (3% of cells). 12, 13 Its expression has been shown to further increase in conditions of steatosis using experimental models of diet-induced NAFLD and chronic liver injury. 14 Thus, through the upregulated ACE2 receptors in patients with NAFLD, SARS-CoV-2 is thought to enter cells in cholangiocytes and cause direct viral damage with resulting hepatic function test abnormalities, including derangements in albumin, gamma-glutamyl transferase, and transaminases, as has been noted in a significant proportion (56%) of hospitalized patients. 15 It is also postulated that a disordered immune response to the virus with immunological damage from excessive inflammatory responses (cytokine storm) contributes to the hepatic injury. 16 Proinflammatory cytokines such as TNFα produced by adipose cells and Kupffer cells cause a dysregulated hepatic innate immunity in patients with NAFLD. This dysregulation results in the decreased activity of proinflammatory M1 macrophages and increased expression of inflammation-suppressing M2 macrophages, thus allowing the progression of COVID-19. 17 Notably, early research identified obesity and increased body mass index (BMI) as being risk factors for severe COVID-19 infection. More recent research has further teased out these nuanced associations. Liver fat in excess of 10% significantly increased the risk for testing positive for COVID-19 and having severe disease (odds ratio [OR]: 2.96). 4 Obesity in the absence of increased liver fat was not shown to be associated with increased risk for testing positive for COVID-19 or having symptomatic disease. However, a metanalytic review of available data shows that among patients with NAFLD with SARS-CoV-2 infection, obesity increases the risk for having severe COVID-19, with an adjusted OR of 6.32. 18 These findings buttress the specific role of liver fat in modulating the susceptibility to SARS-CoV-2 infection and progression.

Given the importance of liver fat in the modulation of COVID-19 infection and progression, it stands to reason that in addition to current therapeutic options, management plans should include targeted options that address reductions in liver fat. Lifestyle interventions and investigational therapies, such as fibroblast growth factor 19 analogues and selective thyroid hormone receptorβ agonists, are potential adjunctive therapies that may specifically benefit patients with NAFLD in the fight against COVID-19.

The current research is, however, far from being conclusive because some authors suggest no direct association between NAFLD and COVID-19 severity/outcomes. 19 However, these studies are somewhat limited by their sample size and coverage, potentially limiting their generalizability. They are also unable to adequately account for potential confounders, including treatment and other severity markers of early-stage COVID-19 infections. In contrast, many clinical studies link NAFLD with poor clinical outcomes, most of which use serological measures (i.e., hepatic steatosis index An Official Learning Resource of AASLD Impact of NAFLD on COVID-19 Infection Asemota and Aduli review and Fibrosis-4 score) that already contain independent predictors (BMI and age, for example) of COVID-19 severity, which introduces confounding that likely exaggerates any association between NAFLD and COVID-19 severity/outcomes. It is therefore imperative for future studies evaluating the true association between NAFLD and COVID-19 severity/outcomes to consider using an independent definition of NAFLD, such as gold standard liver biopsy.

In summary, the current scientific evidence strongly suggests that NAFLD significantly increases the risk for acquiring SARS-CoV-2 infection, as well as the risk for severe and progressive infection. In lieu of current knowledge, prevention and management strategies should incorporate interventions that reduce hepatic fat content. More prospective studies that use independent measures of NAFLD are, however, needed to validate currently reported associations.

E-mail: jasemota@huhosp.org reFerenCes 1) COVID-19 Map

NAFLD and COVID-19: a pooled analysis

Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study

High liver fat associates with higher risk of developing symptomatic COVID-19 infection-initial UK Biobank observations

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

COVID-19: abnormal liver function tests

Clinical features of COVID-19-related Liver functional abnormality

Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis. Front Med

SARS-CoV-2 another kind of liver aggressor, how does it do that?

S3295 SARS-CoV-2 and the gastrointestinal (GI) system: a structured review

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Tissue-based map of the human proteome

COVID-19 and nonalcoholic fatty liver disease: two intersecting pandemics

A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection?

Transaminitis is an indicator of mortality in patients with COVID-19: a retrospective cohort study

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Effect of COVID-19 on preexisting liver disease: what hepatologist should know?

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis

Radiographic hepatic steatosis is not associated with key clinical outcomes among patients hospitalized with COVID-19